New trial: Mark’s coronary heart disease remedy among patients shows encouraging results “Due to the high efficiency rate, the trial was stopped before it was completed” | The company’s announcement did not specify which populations the drug was aimed at, but the experiment was conducted on those who were not vaccinated.
In the past week, the drug “Regeneron” came into use in Israel, with the aim of preventing the exacerbation of the corona among corona patients who are defined as having a mild-moderate condition, and who have a high risk of developing a severe condition. At the same time as the drug went into use, another drug company called Merck on Friday released a trial of a similar drug.
According to the American-German Society, preliminary data from its trial show that taking the drug halved the number of hospitalizations and deaths among those who received it within 5 days of the onset of symptoms.
According to the company, this is how the experiment worked: The 775 people who participated in it were divided into an experiment group and a control group whose members received a placebo. In the first group, the hospitalization rate of the participants was seven percent, and no deaths were recorded at all. In the control group, the hospitalization rate was 14%, and eight of the patients died.
Meanwhile, the company did not specify which populations the drug was intended for, but the trial included high-risk patients who received the treatment at a relatively early stage in their disease. It is important to emphasize, all participants in the experiment were not vaccinated in risk groups.
The announcement from the American-German company claimed that due to the high efficiency rate, an independent expert committee advising it recommended stopping the experiment before it was completed. The company further said that they contacted the FDA and it supported this recommendation. The company also said in a statement that no serious side effects were observed among those who received the drug.